195 related articles for article (PubMed ID: 17350837)
1. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Caenepeel S; Cee VJ; Chaffee SC; Emery M; Fretland J; Gallant P; Gu Y; Johnson RE; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Wang L; Zhao H
Bioorg Med Chem Lett; 2007 May; 17(10):2886-9. PubMed ID: 17350837
[TBL] [Abstract][Full Text] [Related]
2. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
3. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
[TBL] [Abstract][Full Text] [Related]
4. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
9. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
10. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
Cee VJ; Cheng AC; Romero K; Bellon S; Mohr C; Whittington DA; Bak A; Bready J; Caenepeel S; Coxon A; Deak HL; Fretland J; Gu Y; Hodous BL; Huang X; Kim JL; Lin J; Long AM; Nguyen H; Olivieri PR; Patel VF; Wang L; Zhou Y; Hughes P; Geuns-Meyer S
Bioorg Med Chem Lett; 2009 Jan; 19(2):424-7. PubMed ID: 19062275
[TBL] [Abstract][Full Text] [Related]
11. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
12. Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.
Cee VJ; Albrecht BK; Geuns-Meyer S; Hughes P; Bellon S; Bready J; Caenepeel S; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hodous BL; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; McGowan D; Morrison M; Olivieri PR; Patel VF; Polverino A; Powers D; Rose P; Wang L; Zhao H
J Med Chem; 2007 Feb; 50(4):627-40. PubMed ID: 17253679
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
[TBL] [Abstract][Full Text] [Related]
14. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
16. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
[TBL] [Abstract][Full Text] [Related]
17. Optimization of triarylimidazoles for Tie2: influence of conformation on potency.
Johnson NW; Semones M; Adams JL; Hansbury M; Winkler J
Bioorg Med Chem Lett; 2007 Oct; 17(20):5514-7. PubMed ID: 17826092
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
